TY  - GEN
AU  - Ayala,Ernesto
AU  - Figueroa,Javier
AU  - Perkins,Janelle
AU  - Kim,Jongphil
AU  - Yue,Binglin
AU  - Riches,Marcie
AU  - Nishihori,Taiga
AU  - Locke,Frederick
AU  - Anasetti,Claudio
AU  - Kharfan-Dabaja,Mohamed A
TI  - Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma
SN  - 2152-2669
PY  - 2016///0225
KW  - Administration, Intravenous
KW  - Adult
KW  - Aged
KW  - Antineoplastic Agents
KW  - administration & dosage
KW  - Busulfan
KW  - Disease-Free Survival
KW  - Drug Therapy, Combination
KW  - Female
KW  - Graft vs Host Disease
KW  - prevention & control
KW  - Hematopoietic Stem Cell Transplantation
KW  - adverse effects
KW  - Humans
KW  - Immunosuppressive Agents
KW  - therapeutic use
KW  - Lymphoma, Non-Hodgkin
KW  - mortality
KW  - Male
KW  - Methotrexate
KW  - Middle Aged
KW  - Myeloablative Agonists
KW  - Recurrence
KW  - Retrospective Studies
KW  - Survival Rate
KW  - Tacrolimus
KW  - Transplantation Conditioning
KW  - methods
KW  - Transplantation, Homologous
KW  - Vidarabine
N1  - Publication Type: Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/j.clml.2014.12.016
ER  -